Morbid Obesity
Conditions
Keywords
Obesity, Morbid Obesity, Bariatric Surgery, Laparoscopic Gastric Plication
Brief summary
The purpose of this study is to collect data prospectively on the safety and efficacy of the Laparoscopic Gastric Plication operation for patients with Severe or Morbid Obesity. The 95% confidence interval for average percentage of weight loss and body mass index will be computed at 6 months, one year and then annually. Analysis of comorbid conditions changes, quality of life and adverse events will be performed. With 50 subjects in the study, limited power is expected and no formal hypothesis testing will be performed.
Detailed description
The laparoscopic gastric plication (LGP) is a new restrictive bariatric surgical technique that has the potential to eliminate the complications associated with other restrictive procedures (i.e., gastric banding, sleeve gastrectomy) by creating a restriction without the use of an implant and without performing gastric resection. LGP is notably similar to a sleeve gastrectomy in that it generates a gastric tube by means of eliminating the greater curvature but does so without gastric resection.
Interventions
PROCEDURELaparoscopic Gastric Plication
The procedure is performed laparoscopic. The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3-5 cm from the pylorus and ending at the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected. At least two rows stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. A calibration tube or endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure.
Sponsors
Ponce, Jaime, M.D.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Age: 18 - 60 years * BMI 35-39.9 kg/m2 with one or more severe co-morbid conditions or BMI 40-55 kg/m2 * Willingness to comply with dietary restrictions required by the protocol * History of obesity for at least 5 years * History of at least 6 months of documented failures with traditional non-surgical weight loss methods * Willingness to follow protocol requirements which include: signing the informed consent form, completing routine follow-up visits for the study duration, and completing all pre- and post-operative laboratory and diagnostics tests in addition to the quality of life questionnaire * If female with childbearing potential, using an appropriate form of contraception
Exclusion criteria
* Age less than 18, age greater than 60 * Pregnancy * History of major depressive disorder or psychosis * Previous bariatric surgery or previous gastric surgery * Presence of achalasia * Any condition that, in the judgment of the investigator, would place a subject at undue risk, or could potentially compromise the results or interpretation of the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent of excess weight loss | 3 years | The primary efficacy variable is weight loss, which is measured in pounds and evaluated in terms of % excess weight loss (EWL) and body mass index (BMI), both of which will be measured at each follow-up visit. Percent EWL is calculated by the following equation: \[Weight Lost\]/ \[(Pre-op Weight)-(Ideal Body Weight)\]. BMI is calculated by the equation: Weight (kg) divided by Height (m) squared \[kg/m2\]. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Status of comorbid conditions | 3 years | Improvement, resolution or worsening of pre-operative co-morbidities will be evaluated and reported at one year and annually up to 3 years. Status will be evaluated according to the necessity of medications to maintain normal physiologic values such as fasting serum glucose in diabetic patients, normal blood pressure in hypertensive patients, and use of a CPAP machine for patients with obstructive sleep apnea. |
| Changes in quality of life scores from base line | 3 years | Status of quality of life will be evaluated objectively with a standardized SF-36 Health Survey |
| Adverse events | 3 years | Adverse events are intended to be volunteered by subjects or observed by the investigator. All adverse events are to be recorded on appropriate case report forms. |
Countries
United States
Outcome results
None listed